Michael Robern, MD, FRCPC

Dermatology Ottawa Research Centre

885 Meadowlands Drive East, Suite 402
Ottawa, Ontario, Canada
K2C 3N2
613-688-0543

 

Specialty: Dermatology

 

Dr. Michael Robern, Dermatologist


Research Interests: Actinic Keratoses, Arterial Ulcer, Basal Cell Carcinoma, Bowen's Disease, Chronic Wounds, Diabetic Foot Ulcers, Melanoma, Psoriasis, Seborrheic Dermatitis, Skin Cancer of the Head and Neck, Squamous Cell Carcinoma, Venous Stasis Ulcers, Wound Healing

 

Dr. Michael Robern has been practicing dermatology in the Ottawa area since 1994. His clinic specializes in Dermatology and Internal Medicine. Dr. Robern’s current positions also include Assistant Professor at the University of Ottawa. Dr. Robern’s professional memberships include the Canadian Dermatology Association, American Academy of Dermatology, Ottawa Dermatology Society, Canadian Medical Protective Association and the Ontario Medical Association. 

Dr. Robern has been the Principal Investigator on over 17 clinical trials since 1999, and has been involved with clinical trials since the early 1990’s. Dr. Robern has conducted clinical trials in Dermatology for indications including: psoriasis, seborrheic dermatitis, and diabetic foot ulcers.

With a particular interest in wound care and wound care research, Dr. Robern runs special wound care clinics in Ottawa focusing on diabetic foot ulcers and venous stasis ulcers. 

 

Click to view Dr. Michael Robern's Publications

Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med 2016 Dec 15; 375(24): 2335-48. Epub 2016 Sep 30. PMID: 27690741

Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015 Aug 8; 386(9993): 541-51. Epub 2015 Jun 10. PMID: 26072109 / doi: 10.1016/S0140-6736(15)60125-8

Papp KA, Dekoven J, Parsons L, Pirzada S, Robern M, Robertson L, Tan JK. Biologic therapy in psoriasis: Perspectives on associated risks and patient management. J Cutan Med Surg 2012 May-Jun; 16(3): 153-68. PMID: 22713438

Robern M, Olsen Elise A, Kamino Hideko. Diffuse alopecia as the presenting sign of systemic amyloidosis associated with a plasma cell dyscrasia. Unpublished.

Copyright 2014 Probity Medical Research Inc. All Rights Reserved.

Login